Global Hyaluronidase Market is segmented By Type (Animal-derived Hyaluronidase, Synthetic Hyaluronidase), By Application (Dermatology, Chemotherapy, Ophthalmology, Plastic Surgery, Others), By End-user (Hospital, Clinics, Research Centers, Others), and By Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) – Share, Size, Outlook, and Opportunity Analysis, 2024-2031
Market Overview
Global Hyaluronidase Market is expected to grow at a CAGR of 8% during the forecast period 2024-2031
Hyaluronidase is an enzyme solution that can be injected and helps in enhancing the natural degradation of hyaluronic acid. It is a spreading substance that is combined with other medicines and injected under the skin to improvise its absorption by the body when the drug cannot be injected into the vein. It also improves the absorption of radioactive substances during subcutaneous urography.
Market Summary
| Metrics | Details |
| Market CAGR | 8% |
| Segments Covered | By Type, By Application, By End-user, and By Region |
| Report Insights Covered | Competitive Landscape Analysis, Company Profile Analysis, Market Size, Share, Growth, Demand, Recent Developments, Mergers and acquisitions, New Product Launches, Growth Strategies, Revenue Analysis, and Other key insights. |
| Fastest Growing Region | Asia Pacific |
| Largest Market Share | North America |
For More Insights Request Free Sample
Market Dynamics
The global hyaluronidase market growth is driven by the rising penetration across various application areas and the presence of several clinical studies to demonstrate the efficacy of the products is expected to fuel growth in the market.
Rising awareness about the change in physical appearance is expected to drive growth in the forecast period
The rising awareness about the change in physical appearance has led to increasing demand for cosmetics and aesthetic procedures. The demand for hyaluronidase in cosmetic dermatology is increasingly driven by the rise in the prevalence of skin disorders and easy access to advanced cosmetic treatments. Moreover, rising penetration across various application areas and the presence of several clinical studies to determine the efficacy of the products are driving the hyaluronidase market. Moreover, the use of enzyme-based substrates for noninvasive tumor imaging in cancer metastasis, numerous applications in cancer therapy, cosmetic treatments, and ophthalmic therapeutic solutions are also key driving factors in the market. Furthermore, a rise in the number of people opting for aesthetic non-surgical procedures, the rising geriatric population, and favorable reimbursement policies are also expected to drive the hyaluronidase market.
An increase in the incidence of cancer is primarily driving the market for hyaluronidase, expected to drive the market growth
An increase in the incidence of cancer is primarily driving the hyaluronidase market. Cancer is a prominent cause of death worldwide and findings that lead to a cure or control of the disease are a primary goal of several governments globally. Favorable reimbursement policies, an increase in the geriatric population, and a rise in the number of people opting for aesthetic nonsurgical procedures are other factors that are projected to propel the market. Worldwide, the cancer incidence rate has increased to make it the second leading cause of death after cardiovascular disorders. Environmental factors such as changing diet patterns, urbanization, and extended post-reproductive lifespan are responsible for this phenomenon. Thus the increasing prevalence of cancer augments the market growth.
Side effects of available products are likely to hinder the market growth
However, hyaluronidase may cause some unwanted effects. Although not all of these side effects may occur, they may need medical attention. The most frequently reported adverse reactions have been mild local injection sites reactions such as redness, swelling, itching, or pain. anaphylactic-like reactions, and allergic reactions, such as hives, have been reported rarely in patients receiving hyaluronidases.
COVID-19 Impact on Hyaluronidase Market Growth
The COVID-19 pandemic has impacted virtually every aspect of cancer care and research from introducing new risks for cancer patients to disrupting the delivery of cancer treatment and the continuity of cancer research, a review of scientific literature shows. The report, by researchers at Dana-Farber Cancer Institute and other institutions, suggests that while COVID-19 has complicated the treatment of cancer patients, it has also spurred creative solutions to challenges in clinical care, and research into the new disease is benefiting from insights gained over years of cancer research. This factor will hamper the growth of the market in the forecast period.
Market Segmentation Analysis
The Animal-derived hyaluronidase segment is expected to grow at the fastest CAGR during the forecast period (2024-2031)
Animal-derived hyaluronidase is contributing to a high market share attributed to most of the approved and commercialized brands being derived from animal sources only. Bovine and porcine are some of the widely used animal sources. Hydase (PrimaPharma), Vitrase (Bausch &Lomb Incorporated), and Amphadase(Amphastar Pharmaceuticals, Inc.) are some of the brands manufactured by manufacturers. Moreover, the animal-derived hyaluronidase market has witnessed a substantial number of product approvals leading to promoting the growth of the market. For instance, Genentech received FDA approval for Herceptin hylecta which is a subcutaneous injection in which intravenous Herceptin (trastuzumab) and recombinant human hyaluronidase PH20 enzyme help to deliver trastuzumab to the skin for the treatment of breast cancer patients, hence the market is expected to drive the market.
Chemotherapy applications are expected to dominate the Hyaluronidase market during the forecast period
Chemotherapy is one of the types of cancer treatment, which includes the use of one or more chemotherapeutic agents such as animal-derived hyaluronidase. The treatment prevents the division of cancer cells and the growth of cancer cells by killing dividing cells. It is used for the treatment of various types of cancers such as lung cancer, breast cancer, leukemia, myeloma, sarcoma, lymphoma, ovarian cancer, and others. The increasing prevalence of cancer, increasing expenditure on oncology medicine and research, and reimbursements and growing health insurance are driving the growth of the chemotherapeutic segment.
An increase in investment in the research & development of anti-cancer drugs and a rise in demand for advanced cancer drugs also augment the global market. An increase in awareness about cancer and its treatment and early diagnosis is also likely to drive the segment.
Market Geographical Share
North American region holds the largest market share global hyaluronidase market
North America is expected to hold a major market share in the global hyaluronidase market due to the presence of major players manufacturing these products, the high adoption of advanced treatment options, and a substantial number of dermatology clinics prescribing such treatments. Moreover, increasing healthcare expenditure and the presence of well-established healthcare infrastructure are also fueling the growth of the overall regional market to a large extent. According to the American Society of Plastic Surgeons, the number of minimally invasive esthetic procedures performed in the U.S. has been steadily increasing, with an estimated 15.9 million performed in 2015. North America is a developed market with a high rate of adoption of new technology witnessed among end-users. These factors are driving the market growth in the forecast period.
Market Companies and Competitive Landscape
The Hyaluronidase market is moderately competitive with the presence of local as well as global companies. Some of the key players which are contributing to the growth of the market include Prima Pharma, Inc, Amphastar Pharmaceuticals, Inc., Bausch & Lomb Incorporated, Halozyme, Inc., Sun Pharmaceutical Industries Ltd, STEMCELL Technologies, Inc. and CooperSurgical Fertility and Genomic Solutions. Halozyme, Inc, Shreya Life Sciences Pvt. Ltd. among others. The major players are adopting several growth strategies such as product launches, acquisitions, and collaborations, which are contributing to the growth of the hyaluronidase market globally.
Key Companies to Watch
Sun Pharmaceutical Industries Limited.
Overview: Sun Pharmaceutical Industries Limited is a pharmaceutical company. The Company's business segments include US Business, Indian Branded Generics Business, Emerging Markets, Global Consumer Healthcare Business, and Active Pharmaceutical Ingredients (API). Its Rest of the World segment includes Western Europe, Canada, Australia, New Zealand, and other markets. Established in the year 1983, Sun Pharma established brands across niche therapies such as psychiatry, neurology, cardiology, nephrology, gastroenterology, orthopedics, and ophthalmology. The company's office is located in Mumbai.
Product Portfolio: The Company offers its products to therapy areas, such as cardiology, neuropsychiatry, gastroenterology, anti-infective, diabetology, and dermatology. The Company's products include AB PHYLLINE, ABZORB DUSTING POWDER, ACAMPROL, ACOSTIN 3 MIU, ACOSTIN FORTE, and AB PHYLLINE SR 200. Its manufacturing units are situated in India, the United States, and Brazil, among others. Its units produce generics, branded generics, specialty products, over-the-counter (OTC) products, anti-retroviral (ARVs), and APIs. They also produce intermediates in a range of dosage forms, including tablets, capsules, injectables, ointments, creams, and liquids.
